Advertisement
A live audio webcast of the conference call will be available atwww.biomsmedical.com. Please connect at least ten minutes prior to theconference call to ensure adequate time for any software download that may berequired to join the webcast.
Advertisement
Members of the professional investment community are invited toparticipate in the conference call by telephone.
BioMS Medical is a biotechnology company engaged in the development andcommercialization of novel therapeutic technologies. BioMS Medical's leadtechnology, MBP8298, is for the treatment of multiple sclerosis and is beingevaluated in two pivotal phase III clinical trials for secondary progressiveMS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the UnitedStates. It additionally is being evaluated for relapsing remitting MS patientsin a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMSentered into a licensing and development agreement granting Eli Lilly andCompany exclusive worldwide rights to MBP8298 in exchange for an $87 millionupfront payment, milestone payments and escalating royalties on sales. Forfurther information please visit our website at www.biomsmedical.com.
This press release may contain forward-looking statements, which reflectthe Company's current expectation regarding future events. Theseforward-looking statements involve risks and uncertainties that may causeactual results, events or developments to be materially different from anyfuture results, events or developments expressed or implied by suchforward-looking statements. Such factors include, but are not limited to,changing market conditions, the successful and timely completion of clinicalstudies, the establishment of corporate alliances, the impact of competitiveproducts and pricing, new product development, uncertainties related to theregulatory approval process and other risks detailed from time to time in theCompany's ongoing quarterly and annual reporting. Certain of the assumptionsmade in preparing forward-looking statements include but are not limited tothe following: that MBP8298 will continue to demonstrate a satisfactory safetyprofile in ongoing and future clinical trials; and that BioMS Medical Corp.will complete the respective clinical trials within the timelines communicatedin this release. We undertake no obligation to publicly update or revise anyforward-looking statements, whether as a result of new information, futureevents or otherwise.DATE: Friday, May 9, 2008 TIME: 2:00p.m. (Mountain Time), 4:00 p.m. (Eastern Time) DIAL IN NUMBER: 416 644-3430 or 1 800-814-4857 TAPED REPLAY: 1 877-289-8525 or 416 640-1917; available from May 9, 2008 until May 16, 2008 at midnight REFERENCE NUMBER: 21271314 About BioMS Medical Corp. -------------------------
SOURCE BioMS Medical Corp.
